Chi Song

Chi Song

Auto-generated profile, based on publicly available information

Chi Song

U.S. Food and Drug Administration 1 Center for Drug Evaluation and Research Silver Spring, Maryland

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
YSYu H. Sun
Yu H. Sun
AWAnqi Wang
Anqi Wang
CSChi Song
Chi Song
GSGoutham Shankar
Goutham Shankar
RSRajesh K. Srivastava
Rajesh K. Srivastava
XLXin Zhiguo Li
Xin Zhiguo Li
Sperm contributes diverse RNAs to the zygote. While sperm small RNAs have been shown to impact offspring phenotypes, our knowledge of the sperm transcriptome, especially the composition of long RNAs, has been limited by the lack of sensitive, high-throughput experimental techniques that can distinguish intact RNAs from fragmented RNAs, known to abound in sperm. Here, we integrate single-molecule long-read sequencing with short-read sequencing to detect sperm intact RNAs (spiRNAs). We identify 3440 spiRNA species in mice and 4100 in humans. The spiRNA profile consists of both mRNAs and long non-coding RNAs, is evolutionarily conserved between mice and humans, and displays an enrichment in mRNAs encoding for ribosome. In sum, we characterize the landscape of intact long RNAs in sperm, paving the way for future studies on their biogenesis and functions. Our experimental and bioinformatics approaches can be applied to other tissues and organisms to detect intact transcripts.

5 September 2018 in Journal of Medical Internet Research
Verified
Journal Article
Open access
HCHyunyi Cho
Hyunyi Cho
NSNathan Silver
Nathan Silver
KNKilhoe Na
Kilhoe Na
DADinah Adams
Dinah Adams
KLKate T Luong
Kate T Luong
CSChi Song
Chi Song
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Instagram is increasingly becoming a platform on which visual communication of cancer takes place, but few studies have investigated the content and effects. In particular, a paucity of research has evaluated effects of visual communication of cancer on participative engagement outcomes. Objective: The goal of this study was to investigate cancer-related beliefs and emotions shared on Instagram and to examine their effects on participative engagement outcomes including likes, comments, and social support. Methods: This study analyzed the content of 441 posts of #melanomasucks on Instagram and assessed the effects of the content characteristics on outcomes including the number of likes and comments and types of social support using group least absolute shrinkage and selection operator (LASSO) logistic regression. Results: Posts about controlling melanoma were most frequently (61.5%), followed by posts about outcomes of having melanoma (54.4%). Fewer posts were about causes of melanoma (20.4%). A greater number of posts expressed positive (36.1%) than negative emotions (22.7%). Hope was the most frequently expressed emotion (18.1%), followed by fear (11.1%) and humor (10.4%) and sadness (10.4%). Posts about self’s behavior as a cause of melanoma (P < .001) decreased likes and social support comments (P < .048). Posts about physical consequences of melanoma decreased likes (P = .025) but increased comments (P < .001) and emotional social support (P < .001); those about melanoma treatment experience increased comments (P = .033) and emotional social support (P < .001). None of the expressions of positive emotions increased likes, comments, or social support. Expression of anger increased the number of likes (P < .001); but those about fear (P < .001) and joy (P = .006) decreased the number of likes. Posts about fear (P = .003) and sadness (P = .003) increased emotional social support. Conclusions: To our knowledge this is the first investigation of the content and effects of user-generated visual cancer communication on social media. The findings show where the self-expressive and social engagement functions of #melanomasucks converge and diverge, providing implications for extending research on the commonsense model of illness and for developing conceptual frameworks explaining participative engagement on social media.

1 February 2020 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
YSYu H. Sun
Yu H. Sun
JZJiang Zhu
Jiang Zhu
LXLi Huitong Xie
Li Huitong Xie
ZLZiwei Li
Ziwei Li
RMRajyalakshmi Meduri
Rajyalakshmi Meduri
XLXin Zhiguo Li
Xin Zhiguo Li

10 June 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
SCSandra J. Casak
Sandra J. Casak
VKVaibhav Kumar
Vaibhav Kumar
CSChi Song
Chi Song
MYMengdie Yuan
Mengdie Yuan
AAAnup K. Amatya
Anup K. Amatya
LFLola A. Fashoyin-Aje
Lola A. Fashoyin-Aje
On September 2, 2022, the Food and Drug Administration (FDA) approved durvalumab in combination with cisplatin and gemcitabine, for the treatment of patients with unresectable or metastatic biliary tract cancers (BTC). On October 31, 2023, the FDA approved pembrolizumab in combination with cisplatin and gemcitabine for the same indication. Approvals were based on two randomized, multiregional, placebo-controlled trials that randomly allocated patients to receive durvalumab (TOPAZ-1) or pembrolizumab (KEYNOTE-966) in combination with chemotherapy or placebo in combination with chemotherapy. Overall survival (OS) was the primary endpoint in both studies. In both studies, a statistically significant and clinically meaningful improvement in OS was demonstrated. In the TOPAZ-1 trial, the median OS of patients receiving durvalumab was 12.8 months [95% confidence interval (CI), 11.1–14.0] and 11.5 months (95% CI, 10.1–12.5) in patients receiving placebo [hazard ratio (HR), 0.80 (95% CI, 0.66–0.97)]. In the KEYNOTE-966 trial, the median OS of patients receiving pembrolizumab was 12.7 months (95% CI, 11.5–13.6) and 10.9 months (95% CI, 9.9–11.6) in patients receiving placebo [HR, 0.83 (95% CI, 0.72–0.95)]. The addition of checkpoint inhibitors to standard of care chemotherapy for this indication did not reveal any new adverse event signals, and the safety profile was generally consistent with the known clinical experience with durvalumab, pembrolizumab, and the backbone chemotherapy regimen. The approvals of durvalumab and pembrolizumab in combination with standard of care cisplatin and gemcitabine for the treatment of unresectable or metastatic BTC add two new therapeutic options for these patients.

1 February 2021 in Environmental Research
Verified
Journal Article
Closed access
CWChieh-Ming Wu
Chieh-Ming Wu
CSChi (Chuck) Song
Chi (Chuck) Song
RCRyan Chartier
Ryan Chartier
JKJacob Kremer
Jacob Kremer
LNLuke Naeher
Luke Naeher
Olorunfemi AdetonaOlorunfemi Adetona
Olorunfemi Adetona

1 January 1994 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
HLHong Sik Lee
Hong Sik Lee
HJHun Jai Jeon
Hun Jai Jeon
CSChi Wook Song
Chi Wook Song
SLSang Woo Lee
Sang Woo Lee
JCJae Hyun Choi
Jae Hyun Choi
KKKwang Taek Kim
Kwang Taek Kim
Lee HS, et al. J Korean Med Sci. 1994 Apr;9(2):188-196. http://dx.doi.org/10.3346/jkms.1994.9.2.188